托法替尼有哪些雜質？托法替尼原研藥哪里買？

托法替尼的作用機理：

      托法替布（Tofacitinib，CP-690550）是輝瑞公司研發的一種新型口服JAK通路抑制劑。與當前多數其他RA治療藥物主要作用于細胞外靶點不同的是，托法替尼以細胞內信號轉導通路為靶點，作用于細胞因子網絡的核心部分。托法替布（tofacitinib）對JAK3的抑制強度是對JAK1及JAK2的5~100倍。托法替布是開發用于類風濕性關節炎治療的*藥物（first-in-class drug），FDA于2012年11月6日批準了JAK抑制劑tofacitinib用于治療成人活動期及對甲氨蝶呤（MTX）反應不佳的中至重度類風濕關節炎（RA）患者. 
    FDA表示，中到重度的類風濕性關節炎病人，無法從常規口服治療藥物甲氨蝶呤（methotrexate）中獲益或無法耐受治療時，可使用輝瑞的新藥Xeljanz(托法替尼)。托法替尼可單用，也可與甲氨蝶呤及其他特定的標準治療藥物合用。FDA批準Xeljanz一天兩次、每次5毫克的使用劑量。但是同時指出，輝瑞還需提供更深入的數據支持一天兩次、每次10毫克劑量的安全性。 

    深圳遠揚化學可提供托法替尼申報所用全套雜質， 隨貨附CoA證書，HNMR，MS，HPLC圖譜，純度符合申報要求，托法替尼雜質為我司優勢雜質，長期備有庫存，發貨快。如需托法替尼雜質相關詳細信息，歡迎我司業務人員獲取~

    雜質結構式及更多其他雜質對照品，歡迎進入我公司展臺詳細查詢。

我司可供應托法替尼原研藥/原研制劑Xeljanz
商品名（英）: Xeljanz
英文名：tofacitinib
通用名：托法替尼
規格：5mg 60片一瓶
類型：口服
制藥公司：輝瑞
上市時間（美國FDA批準）：2012/11/6
用途：僅供科研實驗使用。
適應癥：對氨甲喋呤治療應答不充分或不耐受的中至重度活動性類風濕關節炎(RA)成人患者。

    除自主品牌雜質對照品外，我司還代理英國NIBSC標準品，美國劍橋CIL同位素標準品，美國NIST標準物質，歐洲標準局IRMM標準物質，加拿大TRC標準品，TLC標準品，MOLCAN標準品，NRC標準品等，歡迎洽談。

附：托法替尼雜質列表：

Tofacitinib

3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

Tofacitinib Impurity 1

N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-1H-indol-4-amine

Tofacitinib Impurity 2

2-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Tofacitinib Impurity 3

3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile

Tofacitinib Impurity 4

3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

Tofacitinib Impurity 5

3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxoprop*

Tofacitinib Impurity 6

3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid

Tofacitinib Impurity 7

N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Tofacitinib Impurity 8

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride

Tofacitinib Impurity 9

(3R,4S)-Tofacitinib with(3S,4R)-Tofacitinib

3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile compound with 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1:1)

Tofacitinib Impurity 10

(3S,4S)-Tofacitinib

3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile

Tofacitinib Impurity 11

(3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride

Tofacitinib Impurity 12

(3S,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride

Tofacitinib Impurity 13

(3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride

Tofacitinib Impurity 14

(3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride

Tofacitinib Impurity 15

3-((3R,4R)-3-(7H-[4,7'-bipyrrolo[2,3-d]pyrimidin]-4'-yl(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile

Tofacitinib Impurity 16

(3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carbaldehyde

Tofacitinib Impurity 17

N-methyl-N-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Tofacitinib Impurity 18

3,3'-((3R,3'R,4R,4'R)-3,3'-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxopropanenitrile)

Tofacitinib Impurity 19

3-(4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-oxopropanenitrile

Tofacitinib Impurity 20

3-((3R,4R)-3-((6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile

Tofacitinib Impurity 21

N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide

Tofacitinib Impurity 22

(3R,4R)-1-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethylpiperidin-3-amine hydrochloride

Tofacitinib Impurity 23

(3R,4R)-N,4-dimethyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine

Tofacitinib Impurity 24

N-((3R,4R)-1,4-dimethylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride

Tofacitinib Impurity 25

1-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone

Tofacitinib Impurity 26

N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine compound with N-((3S,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1:1)

Tofacitinib Impurity 27

N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine